ArticleIrish journal of medical science2025
Cognitive profiling in fibromyalgia patients using the MoCA.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibromyalgia (FM) is characterized by persistent widespread pain, fatigue, sleep problems, and cognitive impairment. Although central sensitization and imbalanced monoamines contribute to FM, the connections between symptom severity, mood, cognition, and duloxetine's effects require more study.
methodsThis cross-sectional case-control study included 145 women (aged 25-60 years) from a tertiary neurology center: 55 healthy controls and 90 FM patients. Of the FM patients, 48 were untreated, while 42 received treatment. Clinical severity was measured by the Fibromyalgia Impact Questionnaire (FIQ), depressive symptoms by the Beck Depression Inventory (BDI), and global/domain cognition by the Montreal Cognitive Assessment (MoCA).
resultsUntreated FM had the highest median FIQ (69.1), followed by treated FM (49.2) and controls (26.1; p < 0.001). The BDI scores followed a similar trend (23.5 vs. 18.0 vs. 10.0; p < 0.001). Untreated FM had lower MoCA total scores (23.0) compared to treated FM (24.0) and controls (27.0). Notable impairments in attention, executive function, and memory were observed in the untreated group. FIQ showed negative correlations with the MoCA total (r = -0.743) and attention (r = -0.637), while BDI correlated negatively with the MoCA total (r = -0.473).
conclusionsThe severity of FM is reflected in the levels of depression and cognitive impairment. These data allow for routine affective and cognitive assessments and a tailored, multidisciplinary FM management approach.
Indexed as
Identifiers
41117879What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.